AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO) $6.77 -0.09 (-1.31%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$6.59▼$6.8950-Day Range$6.17▼$7.6052-Week Range$6.01▼$15.95Volume668,411 shsAverage Volume480,957 shsMarket Capitalization$269.78 millionP/E Ratio42.32Dividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability AngioDynamics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.3% Upside$16.33 Price TargetShort InterestHealthy3.64% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.32) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.81 out of 5 starsMedical Sector52nd out of 952 stocksSurgical & Medical Instruments Industry14th out of 89 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, AngioDynamics has a forecasted upside of 141.3% from its current price of $6.77.Amount of Analyst CoverageAngioDynamics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.64% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 2.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 2.7 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AngioDynamics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions90.52% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.32) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is 42.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.39.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is 42.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.29.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AngioDynamics Stock (NASDAQ:ANGO)AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.Read More ANGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comAngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to KnowNovember 28, 2023 | finance.yahoo.comAngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You TradeDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 23, 2023 | morningstar.comAngioDynamics Inc ANGONovember 22, 2023 | finance.yahoo.comAngioDynamics (ANGO) Outperforms Broader Market: What You Need to KnowNovember 16, 2023 | finance.yahoo.comAngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to NoteNovember 11, 2023 | finance.yahoo.comAngioDynamics (ANGO) Advances But Underperforms Market: Key FactsNovember 8, 2023 | finance.yahoo.comShareholders May Be More Conservative With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation For NowDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 5, 2023 | finance.yahoo.comInvestors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 68% over the last five yearsOctober 9, 2023 | finance.yahoo.comWith 80% ownership of the shares, AngioDynamics, Inc. (NASDAQ:ANGO) is heavily dominated by institutional ownersOctober 6, 2023 | seekingalpha.comAngioDynamics, Inc. (ANGO) Q1 2024 Earnings Call TranscriptOctober 5, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About AngioDynamicsOctober 5, 2023 | finance.yahoo.comQ1 2024 AngioDynamics Inc Earnings CallOctober 5, 2023 | finance.yahoo.comAngioDynamics, Inc. (NASDAQ:ANGO) Q1 2024 Earnings Call TranscriptOctober 4, 2023 | msn.comMedical Devices Player AngioDynamics Exceeds Q1 Expectations, Sticks To Annual GuidanceOctober 4, 2023 | finance.yahoo.comAngioDynamics Inc (ANGO) Reports Strong Q1 2024 Performance, Reaffirms Fiscal Year 2024 GuidanceOctober 4, 2023 | finance.yahoo.comWhy Angiodynamics Stock Sank TodayOctober 4, 2023 | finance.yahoo.comAngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue EstimatesOctober 4, 2023 | washingtonpost.comAngioDynamics: Fiscal Q1 Earnings SnapshotOctober 4, 2023 | markets.businessinsider.comAngioDynamics Inc. Q1 Earnings SummaryOctober 4, 2023 | finance.yahoo.comAngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 GuidanceOctober 3, 2023 | benzinga.comPreview: AngioDynamics's EarningsOctober 3, 2023 | markets.businessinsider.comWhat Wall Street expects from AngioDynamics's earningsSeptember 25, 2023 | markets.businessinsider.comAngioDynamics - Undervalued Gem In Med Tech: Analyst Eyes Stellar Growth With A 'Buy' StanceSeptember 25, 2023 | finance.yahoo.comWhy AngioDynamics Stock Popped on MondaySeptember 17, 2023 | seekingalpha.comAngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity PictureSee More Headlines Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/04/2023Today12/04/2023Next Earnings (Estimated)1/04/2024Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees815Year Founded1988Price Target and Rating Average Stock Price Target$16.33 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+141.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.16 Trailing P/E Ratio42.32 Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,440,000.00 Net Margins1.92% Pretax Margin-1.70% Return on Equity-1.18% Return on Assets-0.90% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio2.01 Sales & Book Value Annual Sales$338.75 million Price / Sales0.80 Cash Flow$1.08 per share Price / Cash Flow6.26 Book Value$9.64 per share Price / Book0.70Miscellaneous Outstanding Shares39,850,000Free Float37,815,000Market Cap$269.78 million OptionableOptionable Beta0.65 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. James C. Clemmer (Age 59)CEO, President & Director Comp: $982.92kMr. Stephen A. Trowbridge (Age 49)Executive VP & CFO Comp: $528.02kMr. David D. Helsel (Age 59)Senior Vice President of Global Operations and R&D Comp: $450.98kMr. Chad T. Campbell (Age 52)Senior VP and GM of Vascular Access & Oncology Global Business Unit Comp: $416.51kMs. Laura Piccinini (Age 54)Senior VP & GM of International Comp: $444.31kMr. Benjamin H. Davis (Age 59)Senior Vice President of Business Development Ms. Marna I. Bronfen-Moore (Age 56)Senior Vice President of Human Resources Mr. Warren G. Nighan (Age 54)Senior Vice President of Quality & Regulatory Affairs Comp: $622.11kMs. Kim L. Seabury (Age 56)Senior Vice President of Information Technology Mr. Scott Centea (Age 44)Senior VP & GM of Endovascular Therapies Comp: $558.54kMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYOrthofix MedicalNASDAQ:OFIXSurmodicsNASDAQ:SRDXAVITA MedicalNASDAQ:RCELUtah Medical ProductsNASDAQ:UTMDView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 6,142 shares on 11/30/2023Ownership: 0.049%Deutsche Bank AGBought 5,025 shares on 11/24/2023Ownership: 0.045%Walleye Capital LLCSold 10,486 shares on 11/21/2023Ownership: 0.051%Jacobs Levy Equity Management Inc.Bought 274,210 shares on 11/17/2023Ownership: 1.792%Diversified Trust CoBought 16,970 shares on 11/17/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions ANGO Stock Analysis - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for AngioDynamics' shares. Their ANGO share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 141.3% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2023? AngioDynamics' stock was trading at $13.77 at the beginning of 2023. Since then, ANGO stock has decreased by 50.8% and is now trading at $6.77. View the best growth stocks for 2023 here. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, January 4th 2024. View our ANGO earnings forecast. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Wednesday, October, 4th. The medical instruments supplier reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The medical instruments supplier earned $78.70 million during the quarter, compared to the consensus estimate of $77.70 million. AngioDynamics had a net margin of 1.92% and a negative trailing twelve-month return on equity of 1.18%. AngioDynamics's revenue was down 3.4% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics updated its FY24 earnings guidance on Wednesday, October, 4th. The company provided earnings per share guidance of ($0.34)-($0.28) for the period, compared to the consensus estimate of ($0.32). The company issued revenue guidance of $328-333 million, compared to the consensus revenue estimate of $328.57 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (2.65%), Jacobs Levy Equity Management Inc. (1.79%), Paradigm Capital Management Inc. NY (1.48%), Tamarack Advisers LP (1.19%), Heartland Advisors Inc. (0.98%) and Northern Trust Corp (0.93%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More This page (NASDAQ:ANGO) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.